Patent · US Active

Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto

US10759803B2 · kind B2 · utility

0Cited by
0References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 8, 2015
Grant dateSep 1, 2020
Priority date—
Expiry dateOct 11, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D471/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.